Investing.com - Adaptimmune Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.05 on revenue of $1.2M. Analysts polled by Investing.com anticipated EPS of $-0.2667 on revenue of $1.53M.
Adaptimmune Therapeutics shares are up 1.48% from the beginning of the year and are trading at $5.560 , down-from-52-week-high.They are under-performing the Nasdaq which is up 22.68% from the start of the year.
Adaptimmune Therapeutics shares gained 1.65% in pre-market trade the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on October 27 with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.38B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar